Table 1.

Subject characteristics

Clinical CharacteristicControlUFTotalP
n39 (35%)74 (65%)113 (100%)
Age (years)55.5 ± 11.554.3 ± 12.654.7 ± 12.20.6
Male31 (79%)48 (65%)79 (70%)0.1
Race0.8
    white3 (8%)9 (12%)12 (11%)
    black35 (90%)63 (85%)98 (87%)
    other1 (3%)2 (3%)3 (3%)
Pre-HD seated BP157.8 ± 15.8/87.0 ± 12.8158.5 ± 16.2/85.5 ± 10.5158.3 ± 16.0/86.0 ± 11.30.8/0.5
Post-HD seated SBP141.5 ± 19.9/77.1 ± 13.2142.9 ± 17.6/78.0 ± 10.1142.4 ± 18.3/77.7 ± 11.20.7/0.7
Pre-HD weight (kg)82.8 ± 16.782.2 ± 20.082.4 ± 18.80.9
Post-HD weight (kg)80.0 ± 16.179.2 ± 19.279.5 ± 18.10.8
Body mass index (kg/m2)26.7 ± 5.926.8 ± 5.726.7 ± 5.70.9
Years on dialysis4.3 ± 6.03.6 ± 4.23.9 ± 4.90.5
Etiology of ESRD0.7
    diabetes mellitus15 (38%)31 (42%)46 (41%)
    hypertension18 (46%)31 (42%)49 (43%)
    glomerulonephritis2 (5%)3 (4%)5 (4%)
    polycystic kidney disease0 (0%)3 (4%)3 (3%)
    other4 (10%)6 (8%)10 (9%)
Current smoker15 (38%)23 (31%)38 (34%)0.4
History of
    congestive heart failure4 (10%)15 (20%)19 (17%)0.2
    myocardial infarction6 (15%)13 (18%)19 (17%)0.8
    stroke4 (10%)7 (9%)11 (10%)0.9
Urea reduction ratio (%)73.0 ± 6.374.2 ± 7.473.8 ± 7.00.4
Albumin (g/dl)3.8 ± 0.43.7 ± 0.53.7 ± 0.50.9
Hemoglobin (g/dl)12.1 ± 1.412.2 ± 1.112.2 ± 1.20.7
Presence of pedal edema7 (18%)16 (22%)23 (20%)0.6
Number receiving anti-hypertensive drugs29 (74%)63 (85%)92 (81%)0.2
Number of anti-hypertensives in users2.1 ± 1.72.2 ± 1.62.1 ± 1.60.8
    Dihydropyridine calcium channel blockers16 (41%)33 (45%)49 (43%)0.7
    Non-dihydropyridine calcium channel blockers2 (5%)4 (5%)6 (5%)0.9
    β-blockers25 (64%)50 (68%)75 (66%)0.7
    α-blockers3 (8%)5 (7%)8 (7%)0.9
    Centrally acting agents8 (21%)21 (28%)29 (26%)0.4
    Vasodilators9 (23%)10 (14%)19 (17%)0.2
    ACE inhibitors20 (51%)38 (51%)58 (51%)1
    Angiotension receptor blockers4 (10%)14 (19%)18 (16%)0.2